1. “Pace of CNS drug development and FDA approvals lags other drug classes,” Tufts Cent. Study Drug Dev., vol. 14, no. 2, 2012.
2. “Longer clinical times are extending time to market for new drugs in US - Tufts CSDD Impact Report 7,” 2005.
3. I. Kola and J. Landis, “Opinion: Can the pharmaceutical industry reduce attrition rates?,” Nat. Rev. Drug Discov., vol. 3, no. 8, pp. 711–716, Aug. 2004.
4. K. I. Kaitin and C. P. Milne, “A Dearth of New Meds,” Sci. Am., vol. 305, no. 2, pp. 16–16, Jul. 2011.
5. “Evaluation of Current Animal Models,” Washington (DC). National Academies Press (US), 2013.